PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the Company will release its fourth quarter and full year 2013 financial results for the period ended December 31, 2013, on Monday, March 3, 2014, after market close. PDL's ...
Tags: Antibodies, Antibody, Biotechnology, Cancer, Healthcare, Investment, Protein
PDL BioPharma has reported a net income of $48.57m, or $0.32 per diluted share, for the third quarter ended 30 September 2012 compared to $45.92m, or $0.28 per diluted share, for the third quarter ended 30 September 2011. Total revenues ...
Tags: PDL BioPharma, royalty revenues, PDL